🔬 What is ProstoX?

ProstoX is a simple, personalized test that analyzes six specific microRNA biomarkers from a blood sample. These markers give insight into how a patient’s normal tissues are biologically likely to respond to radiation—something traditional clinical factors (like age or radiation dose) can’t fully predict.

💡 Why It Matters:

Men with prostate cancer often face difficult decisions about treatment. While radiation can be highly effective, it can also lead to lasting bowel, urinary, or sexual side effects. ProstoX gives men and their doctors an extra layer of personalized data to help make better, safer choices—whether to proceed with radiation, adjust the treatment plan, or consider alternatives like surgery or focal therapy.

📊 What You’ll Learn in This Video:

• How microRNA biomarkers work in predicting radiation sensitivity

• How ProstoX categorizes patients into low, intermediate, or high risk

• Real-world patient examples where ProstoX improved outcomes

• How to use ProstoX in treatment planning (and when to order it)

• Where the test is available and what it costs

• Ongoing efforts to expand access and insurance coverage

💬 Q&A Highlights:

Dr. Weidhaas answers audience questions about:

• Timing of the test (must be done before treatment starts)

• Applicability to different types of radiation (SBRT, IMRT, brachytherapy)

• Future use in other cancers

• Scientific validation and clinical adoption

📍 Bottom Line:

ProstoX brings the power of precision medicine to prostate cancer care. It helps identify men at higher risk of radiation toxicity—before treatment begins—so that decisions can be more informed, personalized, and patient-centered.